logo

For the Inventor, By the Inventor

Cardiff, CA, United States of America

Jennifer Riggs

USPTO Granted Patents = 20 


 

Average Co-Inventor Count = 14.3

ph-index = 9

Forward Citations = 326(Granted Patents)


Company Filing History:

goldMedal20 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2011-2022

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),
2. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),
3. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),
4. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),
5. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),
6. 9623028 - Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof (2017-04-18),
7. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-08-30),
8. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-05-24),
9. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),
10. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),
11. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),
12. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),
13. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),
14. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),
15. 8383634 - Methods of treatment using heteroaryl compounds and compositions thereof (2013-02-26),

Title: The Innovative Contributions of Jennifer Riggs in Pharmaceutical Patents

Introduction: Jennifer Riggs, based in Cardiff, California, is a prominent inventor recognized for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of 20 patents, she has made remarkable advancements in the area of mTOR kinase inhibitors, showcasing her expertise in medicinal chemistry and drug development.

Latest Patents: Among her latest patents is a development focused on substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors. This patent outlines methods for preparing compounds with specific heteroaryl structures. The innovations under her name illustrate her commitment to fighting diseases by inhibiting critical pathways involved in cell growth and proliferation. Additionally, her methodologies for synthesizing various substituted pyrazino[2,3-b]pyrazines further highlight her technical proficiency and inventive capabilities.

Career Highlights: Jennifer Riggs currently works at Signal Pharmaceuticals, Inc., a company known for its dedication to innovative healthcare solutions. Her role at Signal Pharmaceuticals has allowed her to collaborate on various projects aimed at developing new therapeutic agents. Her contributions extend beyond patents, as she plays a crucial role in advancing the company's research and development initiatives.

Collaborations: Throughout her career, Jennifer has worked alongside notable colleagues, including John J. Sapienza and Roy Leonard Harris, III. These collaborations foster a creative environment that encourages the exchange of ideas and leads to the development of groundbreaking inventions in the pharmaceutical industry.

Conclusion: Jennifer Riggs exemplifies the spirit of innovation through her extensive patent portfolio and her contributions to pharmaceutical research. Her work at Signal Pharmaceuticals, combined with her collaborative efforts, positions her as a key figure in the pursuit of new and effective medical treatments. As she continues to push the boundaries of scientific inquiry, her future endeavors are sure to create a lasting impact in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…